ClinicalTrials.gg
CompletedNCT01386658Updated Jun 8, 2021Results posted

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

A Phase 3 interventional study of icatibant in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 26 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
5th of 10
32 · median 26
Started
2012
the only one that year
Phase 3
7 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 5th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with Hereditary Angioedema (HAE) during an initial acute attack.

Read the detailed description

Study HGT-FIR-086 will enroll 30 subjects from 2 to less than 18 years of age, divided into 2 groups: prepubertal and pubertal/postpubertal. At least 10 prepubertal children and at least 20 adolescents (including 10 treated during a HAE attack) must be enrolled in the study.

After a qualifying screening period, the PK, safety/tolerability, and efficacy of treatment with SC icatibant will be evaluated in at least 20 subjects (10 prepubertal and 10 pubertal/postpubertal subjects) who present with cutaneous, abdominal, or laryngeal symptoms of an acute attack of HAE. The PK and safety/tolerability of SC icatibant will be evaluated in at least 10 additional pubertal/postpubertal subjects who meet screening criteria and receive treatment with SC icatibant in the absence of a current acute HAE attack.

The planned duration of active participation for subjects who present with an initial attack of acute HAE will consist of treatment with a single subcutaneous injection of icatibant on Day 1 through follow up at day 90.

After having received initial treatment with icatibant, either during or in the absence of an attack, at least 10 pubertal/postpubertal subjects who subsequently experience an acute HAE attack may continue to receive treatment with icatibant as a single SC administration per attack for a total of 3 eligible icatibant-treated attacks.

The period of active participation in the study for prepubertal subjects will be approximately 90 days, while that for pubertal/postpubertal subjects could be a maximum of approximately 270 or 360 days (3 separate active periods of approximately 90 days for those treated with icatibant during an attack; 4 separate active periods for those treated without an attack), with each active period separated by periods of inactive participation of variable duration.

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • Efficacy
  • Hereditary angioedema
  • HAE
  • Pediatric
  • Children
  • Pharmacokinetics
  • Safety
  • Firazyr
  • icatibant
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Two through \<18 years of age at the time of first HAE attack.

    • Prepubertal and pubertal/postpubertal subjects experiencing and acute cutaneous, abdominal, or laryngeal HAE attack treated with icatibant as part of this study.
    • Pubertal/postpubertal subjects with HAE who are treated with icatibant, but not during an attack.
  2. Documented diagnosis of HAE Type I or II.
  3. (and subject assent as appropriate) signed by the subject's parent(s)or legal guardian(s).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of angioedema other than HAE.
  2. Participation in another clinical trial that involves the use of any product (drug or device)within 30 days prior to study enrollment or at any time during the study.
  3. Any known factor/disease that might interfere with the treatment compliance, study conduct,or result interpretation.
  4. Congenital or acquired cardiac anomalies that interfere significantly with cardiac function.
  5. Treatment with ACE inhibitors within 7 days prior to treatment.
  6. Use of hormonal within the 90 days prior to treatment.
  7. Androgen use (eg, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within the 90 days prior to treatment.
  8. Pregnancy or breastfeeding.
  9. A physical condition that interferes with pubertal status determination.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Icatibant

    Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg

    Drug: icatibant

Interventions

  • Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg

    Also known as: Firazyr

06

What researchers measure

Primary outcomes

  1. Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant

    Time to peak concentration (Tmax) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  2. Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant

    Maximum plasma concentration (Cmax) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  3. Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant

    Total plasma clearance (CL/F) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  4. Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant

    Area under the plasma concentration-time curve from time zero to 4 hours post-dose (AUC0-4) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, and 4 hours post-dose on Day 1

  5. Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant

    Area under the plasma concentration-time curve from time zero to 6 hours post-dose (AUC0-t) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  6. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant

    Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  7. Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant

    Volume of distribution (Vz/F) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  8. Elimination Half-life (t1/2) of a Single Subcutaneous (SC) Dose of Icatibant

    Elimination half-life (t1/2) of a single SC dose of icatibant was reported.

    Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1

  9. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included pulse rate, blood pressure, respiration rate, and temperature. The number of participants who reported clinically significant changes in vital signs were reported.

    Time frame: Pre-dose up to 97 days post-dose

  10. Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)

    A standard 12-lead ECG was performed after 10 minutes at rest when the participant was seated or supine following treatment. The number of participants who reported clinically significant changes in ECGs were reported.

    Time frame: 6 - 8 hours post-dose on Day 1

  11. Number of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations

    Clinical laboratory evaluations included clinical chemistry (including liver function tests), hematology, urinalysis. The number of participants who reported clinically significant changes in clinical laboratory evaluations were reported.

    Time frame: Pre-dose up to 97 days post-dose

  12. Number of Participants Who Reported Presence of Anti-icatibant Antibodies

    The number of participants who reported anti-icatibant antibodies were reported.

    Time frame: Pre-dose up to 97 days post-dose

  13. Number of Participants With Adverse Events (AEs)

    An AE was any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in a clinical study, whether or not considered investigational product related.

    Time frame: From the start of study drug administration up to 97 days post-dose

  14. Number of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 1

    The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occured after initial icatibant administration was reported.

    Time frame: 1 h post-dose on Day 1 up to 9 days post-dose

  15. Number of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 2 and 3

    The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occurred after subsequent icatibant administration by study-site personnel (health care practitioner \[HCP\] administration) or by caregiver/self (caregiver administration) was reported. In the below table, E-2 refers to icatibant exposure 2 and E-3 refers to icatibant exposure 3.

    Time frame: 1 h post-dose up to 9 days post-dose

  16. Number of Participants With Clinically Significant Changes in Reproductive Hormones

    Reproductive hormone levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone in females, and FSH, LH, and testosterone in males were measured. The number of participants with clinically significant changes in reproductive hormones was reported.

    Time frame: Pre-dose up to 97 days post-dose

Secondary outcomes

  1. Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1

    The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20 percent (%) improvement in the average post-treatment symptom score with no worsening of any single component score for the initial icatibant exposure. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of hereditary angioedema (HAE) using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received initial icatibant administration was reported.

    Time frame: From start of study drug administration up to 8.5 hours post-dose

  2. Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3

    The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20% improvement in the composite (or average) post-treatment symptom score with no worsening of any single component score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

    Time frame: From start of study drug administration up to 12 hours post-dose

  3. Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1

    The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received initial icatibant administration was reported.

    Time frame: From start of study drug administration up to 52 hours post-dose

  4. Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3

    The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

    Time frame: From start of study drug administration up to 28 hours post-dose

  5. Time to Onset of Symptom Relief (TOSR) for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores

    The TOSR was defined as the earliest time at which a 20% improvement was seen in the total post-treatment score. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. Face(F): 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); Legs(L): 0 (normal position/relaxed) - 2 (kicking/legs drawn up); Activity(A): 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); Cry(C): 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); Consolability(C): 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.

    Time frame: From start of study drug administration up to 8.5 hours post-dose

  6. Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1

    Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received initial icatibant administration was reported.

    Time frame: From start of study drug administration up to 8.5 hours post-dose

  7. Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3

    Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

    Time frame: From start of study drug administration up to 12 hours post-dose

  8. Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1

    Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received initial icatibant administration was reported.

    Time frame: From start of study drug administration up to 52 hours post-dose

  9. Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3

    Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

    Time frame: From start of study drug administration up to 28 hours post-dose

  10. Time to Minimum Symptom for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores

    Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which the total post-treatment score improved to zero. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. (F) Face: 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); (L) Legs: 0 (normal position/relaxed) - 2 (kicking/legs drawn up); (A) Activity: 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); (C) Cry: 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); (C) Consolability: 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.

    Time frame: From start of study drug administration up to 8.5 hours post-dose

  11. Time to Use of Rescue Medication for the Treatment of Symptoms of the Hereditary Angioedema (HAE) Attack Following Study Drug Administration

    Rescue medication was any medication used after the administration of icatibant which, in the opinion of the investigator, was immediately necessary to alleviate acute symptoms which are judged by the investigator as resultant from the current HAE attack. Time to first use of rescue medication prior to the onset of symptom relief was calculated from the time of study drug administration to the first use of rescue medication prior to the onset of symptom relief. This analysis was not performed since as per protocol, "This analysis will only be performed if there are at least 5 participants for a given attack who used rescue medication prior to attaining symptom relief".

    Time frame: From the start of study drug administration up to 52 hours post-dose

  12. Number of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 1

    The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours postdose were reported.

    Time frame: From 2 hours post-dose to 4 hours post-dose

  13. Number of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 2 and 3

    The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours post-dose were reported.

    Time frame: From 2 hours post-dose to 4 hours post-dose

07

Results

Posted Mar 25, 2019

Participant flow

The study was conducted at 27 study centers in the United States, Germany, Israel, Spain, Argentina, Australia, Austria, Canada, Colombia, Hungary, and Italy between 27 January 2012 (first participant first visit) and 12 March 2018 (last participant last visit).

Initial Icatibant Exposure
Participant flow — Initial Icatibant Exposure
MilestonePrepubertalPubertal/Postpubertal
Started1121
Completed119
Not completed012
Withdrew: Withdrawal by subject09
Withdrew: Lack of adherence and poor compliance03
Icatibant Exposure 2
Participant flow — Icatibant Exposure 2
MilestonePrepubertalPubertal/Postpubertal
Started09
Completed09
Not completed00
Icatibant Exposure 3
Participant flow — Icatibant Exposure 3
MilestonePrepubertalPubertal/Postpubertal
Started09
Completed09
Not completed00

Outcome measures

PrimaryTime to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant

Time to peak concentration (Tmax) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · Hour (h)
Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant
Hour (h)PrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant0.42 ± 0.130.55 ± 0.190.57 ± 0.17
PrimaryMaximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant

Maximum plasma concentration (Cmax) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant
Nanogram per milliliter (ng/mL)PrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant659 ± 158805 ± 125761 ± 133
PrimaryTotal Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant

Total plasma clearance (CL/F) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · Milliliters per minute (mL/min)
Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant
Milliliters per minute (mL/min)PrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant10.8 ± 4.6313.1 ± 3.4219.3 ± 4.84
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant

Area under the plasma concentration-time curve from time zero to 4 hours post-dose (AUC0-4) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, and 4 hours post-dose on Day 1
Reported as:
Mean · Hour*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant
Hour*nanogram per milliliter (h*ng/mL)PrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant1241 ± 3191448 ± 3041335 ± 211
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant

Area under the plasma concentration-time curve from time zero to 6 hours post-dose (AUC0-t) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant
h*ng/mLPrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant1289 ± 3251573 ± 3721398 ± 225
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant

Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant
h*ng/mLPrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant1243 ± 2441710 ± 5691416 ± 229
PrimaryVolume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant

Volume of distribution (Vz/F) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · Liters (L)
Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant
Liters (L)PrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant12.5 ± 5.2823.5 ± 13.925.4 ± 8.87
PrimaryElimination Half-life (t1/2) of a Single Subcutaneous (SC) Dose of Icatibant

Elimination half-life (t1/2) of a single SC dose of icatibant was reported.

Time frame:
Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Reported as:
Mean · h
Elimination Half-life (t1/2) of a Single Subcutaneous (SC) Dose of Icatibant
hPrepubertalPubertal/Postpubertal: With Acute AttackPubertal/Postpubertal: Without Acute Attack
Elimination Half-life (t1/2) of a Single Subcutaneous (SC) Dose of Icatibant0.80 ± 0.041.34 ± 0.960.90 ± 0.10
PrimaryNumber of Participants With Clinically Significant Changes in Vital Signs

Vital signs included pulse rate, blood pressure, respiration rate, and temperature. The number of participants who reported clinically significant changes in vital signs were reported.

Time frame:
Pre-dose up to 97 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsPrepubertalPubertal/Postpubertal
Number of Participants With Clinically Significant Changes in Vital Signs00
PrimaryNumber of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)

A standard 12-lead ECG was performed after 10 minutes at rest when the participant was seated or supine following treatment. The number of participants who reported clinically significant changes in ECGs were reported.

Time frame:
6 - 8 hours post-dose on Day 1
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)
ParticipantsPrepubertalPubertal/Postpubertal
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)00
PrimaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations

Clinical laboratory evaluations included clinical chemistry (including liver function tests), hematology, urinalysis. The number of participants who reported clinically significant changes in clinical laboratory evaluations were reported.

Time frame:
Pre-dose up to 97 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations
ParticipantsPrepubertalPubertal/Postpubertal
Number of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations00
PrimaryNumber of Participants Who Reported Presence of Anti-icatibant Antibodies

The number of participants who reported anti-icatibant antibodies were reported.

Time frame:
Pre-dose up to 97 days post-dose
Reported as:
Count of participants · Participants
Number of Participants Who Reported Presence of Anti-icatibant Antibodies
ParticipantsPrepubertalPubertal/Postpubertal
Number of Participants Who Reported Presence of Anti-icatibant Antibodies00
PrimaryNumber of Participants With Adverse Events (AEs)

An AE was any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in a clinical study, whether or not considered investigational product related.

Time frame:
From the start of study drug administration up to 97 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPrepubertalPubertal/Postpubertal
Number of Participants With Adverse Events (AEs)211
PrimaryNumber of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 1

The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occured after initial icatibant administration was reported.

Time frame:
1 h post-dose on Day 1 up to 9 days post-dose
Reported as:
Count of participants · Participants
Number of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 1
ParticipantsPrepubertalPubertal/Postpubertal
Any Reaction920
Any Severe Reaction02
PrimaryNumber of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 2 and 3

The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occurred after subsequent icatibant administration by study-site personnel (health care practitioner \[HCP\] administration) or by caregiver/self (caregiver administration) was reported. In the below table, E-2 refers to icatibant exposure 2 and E-3 refers to icatibant exposure 3.

Time frame:
1 h post-dose up to 9 days post-dose
Reported as:
Count of participants · Participants
Number of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 2 and 3
ParticipantsPubertal/Postpubertal
E-2: HCP Administration: Any Reaction1
E-2: HCP Administration: Any Severe Reaction0
E-2: Caregiver Administration: Any Reaction8
E-2: Caregiver Administration: Any Severe Reaction3
E-3: HCP Administration: Any Reaction1
E-3: HCP Administration: Any Severe Reaction0
E-3: Caregiver Administration: Any Reaction7
E-3: Caregiver Administration: Any Severe Reaction1
PrimaryNumber of Participants With Clinically Significant Changes in Reproductive Hormones

Reproductive hormone levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone in females, and FSH, LH, and testosterone in males were measured. The number of participants with clinically significant changes in reproductive hormones was reported.

Time frame:
Pre-dose up to 97 days post-dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Reproductive Hormones
ParticipantsPrepubertalPubertal/Postpubertal
Number of Participants With Clinically Significant Changes in Reproductive Hormones00
SecondaryTime to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1

The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20 percent (%) improvement in the average post-treatment symptom score with no worsening of any single component score for the initial icatibant exposure. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of hereditary angioedema (HAE) using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received initial icatibant administration was reported.

Time frame:
From start of study drug administration up to 8.5 hours post-dose
Reported as:
Median · h
Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1
hPrepubertalPubertal/Postpubertal
Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
SecondaryTime to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3

The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20% improvement in the composite (or average) post-treatment symptom score with no worsening of any single component score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

Time frame:
From start of study drug administration up to 12 hours post-dose
Reported as:
Median · h
Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3
hPubertal/Postpubertal
Icatibant Exposure-2: HCP Administration4.0 (NA to NA)
Icatibant Exposure-2: Caregiver Administration1.0 (1.0 to 2.3)
Icatibant Exposure-3: HCP Administration1.0 (NA to NA)
Icatibant Exposure-3:Caregiver Administration1.1 (1.0 to 3.0)
SecondaryTime to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1

The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received initial icatibant administration was reported.

Time frame:
From start of study drug administration up to 52 hours post-dose
Reported as:
Median · h
Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1
hPrepubertalPubertal/Postpubertal
Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 10.9 (0.8 to 1.0)1.0 (0.6 to 1.0)
SecondaryTime to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3

The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

Time frame:
From start of study drug administration up to 28 hours post-dose
Reported as:
Median · h
Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3
hPubertal/Postpubertal
Icatibant Exposure-2: HCP Administration3.0 (NA to NA)
Icatibant Exposure-2: Caregiver Administration1.0 (1.0 to 1.2)
Icatibant Exposure-3: HCP Administration1.0 (NA to NA)
Icatibant Exposure-3:Caregiver Administration1.1 (1.0 to 1.2)
SecondaryTime to Onset of Symptom Relief (TOSR) for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores

The TOSR was defined as the earliest time at which a 20% improvement was seen in the total post-treatment score. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. Face(F): 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); Legs(L): 0 (normal position/relaxed) - 2 (kicking/legs drawn up); Activity(A): 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); Cry(C): 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); Consolability(C): 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.

Time frame:
From start of study drug administration up to 8.5 hours post-dose
Reported as:
Median · h
Time to Onset of Symptom Relief (TOSR) for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores
hPrepubertal
Time to Onset of Symptom Relief (TOSR) for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores1.0 (NA to NA)
SecondaryTime to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1

Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received initial icatibant administration was reported.

Time frame:
From start of study drug administration up to 8.5 hours post-dose
Reported as:
Median · h
Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1
hPrepubertalPubertal/Postpubertal
Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 11.9 (1.0 to 2.0)1.0 (1.0 to 2.0)
SecondaryTime to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3

Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

Time frame:
From start of study drug administration up to 12 hours post-dose
Reported as:
Median · h
Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3
hPubertal/Postpubertal
Icatibant Exposure-2: Caregiver Administration1.2 (1.0 to 2.0)
Icatibant Exposure-3: Caregiver Administration2.2 (1.0 to NA)
SecondaryTime to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1

Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received initial icatibant administration was reported.

Time frame:
From start of study drug administration up to 52 hours post-dose
Reported as:
Median · h
Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1
hPrepubertalPubertal/Postpubertal
Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 12.4 (1.9 to 5.3)3.8 (1.0 to 6.8)
SecondaryTime to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3

Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.

Time frame:
From start of study drug administration up to 28 hours post-dose
Reported as:
Median · h
Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3
hPubertal/Postpubertal
Icatibant Exposure-2: HCP Administration3.0 (NA to NA)
Icatibant Exposure-2: Caregiver Administration2.1 (1.0 to 4.0)
Icatibant Exposure-3: HCP Administration5.8 (NA to NA)
Icatibant Exposure-3:Caregiver Administration24.0 (3.8 to 24.2)
SecondaryTime to Minimum Symptom for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores

Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which the total post-treatment score improved to zero. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. (F) Face: 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); (L) Legs: 0 (normal position/relaxed) - 2 (kicking/legs drawn up); (A) Activity: 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); (C) Cry: 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); (C) Consolability: 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.

Time frame:
From start of study drug administration up to 8.5 hours post-dose
Reported as:
Median · h
Time to Minimum Symptom for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores
hPrepubertal
Time to Minimum Symptom for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores1.0 (NA to NA)
SecondaryTime to Use of Rescue Medication for the Treatment of Symptoms of the Hereditary Angioedema (HAE) Attack Following Study Drug Administration

Rescue medication was any medication used after the administration of icatibant which, in the opinion of the investigator, was immediately necessary to alleviate acute symptoms which are judged by the investigator as resultant from the current HAE attack. Time to first use of rescue medication prior to the onset of symptom relief was calculated from the time of study drug administration to the first use of rescue medication prior to the onset of symptom relief. This analysis was not performed since as per protocol, "This analysis will only be performed if there are at least 5 participants for a given attack who used rescue medication prior to attaining symptom relief".

Time frame:
From the start of study drug administration up to 52 hours post-dose
Reported as:
Median · h
Time to Use of Rescue Medication for the Treatment of Symptoms of the Hereditary Angioedema (HAE) Attack Following Study Drug Administration
hPrepubertalPubertal/Postpubertal
Time to Use of Rescue Medication for the Treatment of Symptoms of the Hereditary Angioedema (HAE) Attack Following Study Drug AdministrationNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 1

The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours postdose were reported.

Time frame:
From 2 hours post-dose to 4 hours post-dose
Reported as:
Count of participants · Participants
Number of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 1
ParticipantsPrepubertalPubertal/Postpubertal
Abdominal Tenderness01
Nausea00
Vomiting00
Diarrhea00
Skin Pain00
Erythema00
Skin Irritation00
Skin Swelling00
SecondaryNumber of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 2 and 3

The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours post-dose were reported.

Time frame:
From 2 hours post-dose to 4 hours post-dose
Reported as:
Count of participants · Participants
Number of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 2 and 3
ParticipantsPubertal/Postpubertal
E-2: HCPA: Abdominal Tenderness0
E-2:CA: Abdominal Tenderness0
E-2: HCPA: Nausea0
E-2: CA: Nausea0
E-2:HCPA: Vomiting0
E-2: CA: Vomiting0
E-2: HCPA: Diarrhea0
E-2: CA: Diarrhea0
E-2: HCPA: Skin Pain0
E-2: CA: Skin Pain0
E-2: HCPA: Erythema0
E-2: CA: Erythema0
E-2: HCPA: Skin Irritation0
E-2: CA: Skin Irritation0
E-2: HCPA: Skin Swelling0
E-2: CA: Skin Swelling0
E-2: HCPA: Dysphagia0
E-2: CA: Dysphagia0
E-2: HCPA: Voice Change0
E-2: CA: Voice Change0
E-2: HCPA: Breathing Difficulties0
E-2: CA: Breathing Difficulties0
E-2: HCPA: Stridor0
E-2: CA: Stridor0
E-2: HCPA: Asphyxia0
E-2:CA: Asphyxia0
E-3: HCPA: Abdominal Tenderness0
E-3: CA: Abdominal Tenderness1
E-3: HCPA: Nausea0
E-3: CA: Nausea0
E-3: HCPA: Vomiting0
E-3: CA: Vomiting0
E-3: HCPA: Diarrhea0
E-3: CA: Diarrhea1
E-3: HCPA: Skin Pain0
E-3: CA: Skin Pain0
E-3: HCPA: Erythema0
E-3: CA: Erythema0
E-3: HCPA: Skin Irritation0
E-3: CA: Skin Irritation0
E-3: HCPA: Skin Swelling0
E-3: CA: Skin Swelling0
E-3: HCPA: Dysphagia0
E-3: CA: Dysphagia0
E-3: HCPA: Voice Change0
E-3: CA: Voice Change0
E-3: HCPA: Breathing Difficulties0
E-3: CA: Breathing Difficulties0
E-3: HCPA: Stridor0
E-3: CA: Stridor0
E-3: HCPA: Asphyxia0
E-3: CA: Asphyxia0

Adverse events

Collected over From start of study drug administration up to 187 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prepubertal0/11 (0%)0/11 (0%)4/11 (36.4%)
Pubertal/Post-pubertal0/21 (0%)0/21 (0%)8/21 (38.1%)
Overall0/32 (0%)0/32 (0%)12/32 (37.5%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPrepubertalPubertal/Post-pubertalOverall
NasopharyngitisInfections and infestations0/113/213/32
ConjunctivitisEye disorders0/112/212/32
Conjunctivitis allergicEye disorders0/112/212/32
ToothacheGastrointestinal disorders0/112/212/32
PyrexiaGeneral disorders0/112/212/32
Upper respiratory tract infectionInfections and infestations1/112/213/32
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/112/212/32
AnaemiaBlood and lymphatic system disorders1/110/211/32
ArthralgiaMusculoskeletal and connective tissue disorders1/110/211/32
Epiphyseal fractureInjury, poisoning and procedural complications1/110/211/32

Baseline characteristics

Safety population consisted of participants who were treated with icatibant at least once during the study.

Age, Continuous
Age, Continuous(Years)PrepubertalPubertal/PostpubertalTotal
Mean8.6 ± 2.9714.3 ± 1.6612.3 ± 3.48
Sex: Female, Male
Sex: Female, Male(Participants)PrepubertalPubertal/PostpubertalTotal
Female5813
Male61319
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PrepubertalPubertal/PostpubertalTotal
Hispanic or Latino123
Not Hispanic or Latino101929
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PrepubertalPubertal/PostpubertalTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White112031
More than one race000
Unknown or Not Reported011
08

Study locations

26 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Breathe America
    Shreveport, Louisiana 71106, United States
  • Institute for Asthma and Allergy, PC
    Chevy Chase, Maryland 20815, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63141, United States
  • Bernstein Clinical Research Center, LLC
    Cincinnati, Ohio 45231, United States
  • Toledo Institute of Clinical Research
    Toledo, Ohio 43617, United States
  • Oklahoma Institute of Allergy and Asthma Clinical Research, LLC
    Oklahoma City, Oklahoma 73131, United States
  • Allergy Asthma Dermatology Research Center
    Lake Oswego, Oregon 97035, United States
  • Penn State University
    Hershey, Pennsylvania 17033, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • Medizinische Universität Graz Hautklinik
    Graz, 8036, Austria
  • McMaster University
    Hamilton, Ontario L8S 4K1, Canada
  • Hospital Infantil Universitario de San Jose
    Bogota, Cundinamarca, Colombia
  • Klinikum der Johann Wolfgang Goethe University
    Frankfurt, 60590, Germany
  • Johannes-Gutenberg University Clinical Research Center
    Mainz, 55131, Germany
  • HZRM Hämophilie Zentrum Rhein Main GmbH
    Walldorf, 64546, Germany
  • Heim Pal Childrens Hospital
    Budapest, H-1131, Hungary
  • Bnai Zion Medical Center, Allergy and Immunology Institute
    Haifa, Israel
  • Tel Aviv Sourasky Medical Center, Pulmonology and Allergy Unit
    Tel Aviv, 64239, Israel
  • Sheba Medical Center Allergy and Immunology Angioedema Center
    Tel Hashomer, 52621, Israel
  • University of Naples Federico II, Dipartimento di Medicina Interna
    Naples, 80131, Italy
  • Unidad de Alergia, Edif. Consultas Externas, Planta Baja HOSPITAL UNIVERSITARIO LA PAZ
    Madrid, 28046, Spain
  • University Hospital, Pediatric Pulmonology and Allergy Unit
    Valencia, 46026, Spain
09

References and documents

Publications

  • Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J, Nothaft W, Schranz J, Bernstein JA, Li HH. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1671-1678.e2. doi: 10.1016/j.jaip.2017.04.010. Epub 2017 Jun 7. PubMed 28601641 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Mar 2018, 73 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 73 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2011
First posted
Jul 1, 2011
StartActual
Jan 27, 2012
Primary completionActual
Mar 12, 2018
CompletionActual
Mar 12, 2018
Results first posted
Mar 25, 2019
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01386658
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 1, 2011
Start date
Jan 27, 2012
Primary completion
Mar 12, 2018
Completion
Mar 12, 2018
Results posted
Mar 25, 2019
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion